Efficacy and Safety of Amantadine Hydrochloride (HCl) ER Tablets to Treat Parkinson's Disease Patients With LID.

ClinicalTrials.gov ID: NCT02153645

Public ClinicalTrials.gov record NCT02153645. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 23, 2026, 2:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized, Placebo-controlled, Double-blind, 16 Week Study to Evaluate the Efficacy and Safety of Amantadine HCl Extended Release Tablets in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesias

Study identification

NCT ID: NCT02153645
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 3
Lead sponsor: Adamas Pharmaceuticals, Inc.; Industry
Enrollment: 87 participants

Conditions and interventions

Conditions

Interventions

240mg Amantadine HCl ER tablets Drug
Placebo tablets Drug
320mg Amantadine HCl ER tablets Drug

Drug

Eligibility (public fields only)

Age range: 30 Years to 85 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Aug 17, 2014
Primary completion: May 19, 2016
Completion: May 19, 2016
Last update posted: Feb 15, 2022

2014 – 2016

United States locations

U.S. sites: 26
U.S. states: 15
U.S. cities: 24

Facility	City	State	ZIP	Site status
Not listed	Tucson	Arizona	85724	—
Not listed	Fountain Valley	California	92708	—
Not listed	Irvine	California	92697	—
Not listed	Pasadena	California	91105	—
Not listed	Reseda	California	91335	—
Not listed	Ventura	California	93001	—
Not listed	Ventura	California	93003	—
Not listed	Boulder	Colorado	80304	—
Not listed	Hollywood	Florida	33021	—
Not listed	Miami	Florida	33101	—
Not listed	North Palm Beach	Florida	33403	—
Not listed	Tampa	Florida	33612	—
Not listed	Chicago	Illinois	60612	—
Not listed	Indianapolis	Indiana	46202	—
Not listed	Baton Rouge	Louisiana	70810	—
Not listed	Ann Arbor	Michigan	48103	—
Not listed	Ann Arbor	Michigan	48109	—
Not listed	Summit	New Jersey	07901	—
Not listed	Brooklyn	New York	11203	—
Not listed	Manhasset	New York	11020	—
Not listed	Patchogue	New York	11772	—
Not listed	Raleigh	North Carolina	27612	—
Not listed	Columbus	Ohio	43221	—
Not listed	Round Rock	Texas	78681	—
Not listed	Orem	Utah	84058	—
Not listed	Kirkland	Washington	98034	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 30 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02153645, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Feb 15, 2022 · Synced Jul 23, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02153645 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →